Drug Profile
Research programme: anti-CD137 monoclonal antibodies - Nanjing Galaxy Biopharmaceutical
Alternative Names: anti-CD137 monoclonal antibodies – Nanjing Galaxy Biopharmaceutical; anticancer antibodies – Nanjing Galaxy BiopharmaceuticalLatest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Nanjing Galaxy Biopharmaceutical
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD137 antigen agonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in China
- 05 Apr 2017 Preclinical trials in Cancer in China prior to April 2017 (unspecified route)